Article Figures & Data
Figures
- FIGURE 1.
A 60-y-old woman with NHL and complete response after 90Y-ibritumomab treatment. (A) No lesions are seen on anterior whole-body planar pretherapy 111In-ibritumomab scan (images from 48-h scan are shown). (B) Pretherapy (1 mo) MIP image of 18F FDG PET shows abdominal lesions (arrowheads). (C) MIP image of 18F FDG PET after therapy (3 mo) is negative for active disease.
- FIGURE 2.
A 45-y-old man with NHL and progressive disease after 90Y-ibritumomab treatment. (A) Lesions are seen in abdominal region (arrowheads) on anterior whole-body planar pretherapy 111In-ibritumomab scan (images from 48-h scan are shown). (B and C) Pretherapy (1 mo) MIP image of 18F FDG PET (B) and posttherapy (4 mo) MIP of 18F FDG PET (4 mo apart) (C) show progression of lesions noted before therapy (arrowheads).
Tables
Day Procedure Agent 0 Preloading Rituximab, 250 mg/m2 0 Injection 111In-ibritumomab, 185 MBq (5 mCi) 0, 1, 2, and 3 Whole-body scanning 111In-ibritumomab 7 Preloading Rituximab, 250 mg/m2 7 Injection 90Y-ibritumomab, 15 MBq/kg (0.4 mCi/kg) - TABLE 2
Correlation of 111In-Ibritumomab Pretherapy Scans and Outcomes of 90Y-Ibritumomab Therapy in Studied Population
Pretherapy scan findings Outcome Positive Negative Complete response (9/28) 2 7 Partial response (8/28) 7 1 Mixed response (4/28) 4 0 No change (4/28) 3 1 Progressive disease (3/28) 3 0 Data are numbers of patients with positive or negative 111In-ibritumomab findings before therapy.
Jump to section
Related Articles
Cited By...
- Theranostics in Hematooncology
- Reply: Tumor Metabolic Phenotypes on 18F FDG PET
- Tumor Metabolic Phenotypes on 18F FDG PET
- Some like it hot: lymphoma radioimmunotherapy
- A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy